Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Items 301–400 of 660
Arslan, B., Andréasson, U., Rembeza, E., Axelsson, M., Novakova, L., Kirsebom, B., Fladby, T., Dittrich, A., Kern, S., Skoog, I. G., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0870 · Cited by 9
Self-citationDavydow, D. S., Brasfield, M., Morrow, C. B., Staffaroni, A. M., Pontone, G. M., & Asken, B. M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2429 · Cited by 9
Katsigianni, S., & Koutsouraki, E. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05914-9 · Cited by 9
Relationships between PET and blood plasma biomarkers in corticobasal syndrome
Singh, N. A., Alnobani, A., Graff‐Radford, J., Machulda, M. M., Mielke, M. M., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., Kanekiyo, T., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13914 · Cited by 9
Yao, J., Dai, X., Yv, X., Zheng, L., Zheng, J., Kuang, B., Teng, W., Yu, W., Li, M., Cao, H., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1541230 · Cited by 9
Álvarez‐Sánchez, L., Peña‐Bautista, C., Ferré‐González, L., Balaguer, Á., Amengual, J. L., Baquero, M., & Cháfer‐Pericás, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-01511-3 · Cited by 9
Evaluation of Blood-Based Diagnostic Biomarkers for Canine Cognitive Dysfunction Syndrome
Yoon, J.-W., Nam, C.-S., Lee, K.-S., Dan, T.-J., Jeon, H.-J., Kang, M., & Park, H. (2025) · Animals · doi:10.3390/ani15131974 · Cited by 9
Deletion of MyD88 in astrocytes prevents β‐amyloid‐induced neuropathology in mice
Huat, T. J., Onraet, T., Camats‐Perna, J., Newcombe, E. A., Ngo, K. C., Sue, A. N., Mirzaei, M., LaFerla, F. M., & Medeiros, R. (2022) · Glia · doi:10.1002/glia.24285 · Cited by 10
Early Alzheimer’s Disease Screening Approach Using Plasma Biomarkers
Álvarez‐Sánchez, L., Peña‐Bautista, C., Ferré‐González, L., Cubas-Núñez, L., Balaguer, Á., Casanova-Estruch, B., Baquero, M., & Cháfer‐Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814151 · Cited by 9
Zhu, S., Shi, J., Jin, Q., Zhang, Y., Zhang, R., Chen, X., Wang, C., Shi, T., & Li, L. (2023) · Aging · doi:10.18632/aging.205087 · Cited by 9
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Ma, Y., Zhang, J., Liu, H., Li, D., Guo, S., Han, J., Wang, L., Yu, S., Su, X., Gao, Y., et al. (2025) · Protein & Cell · doi:10.1093/procel/pwaf042 · Cited by 8
Puravet, A., Sapin, V., Bouillon‐Minois, J., Pereira, B., Durif, J., Bouthors, B., Moustafa, F., Schmidt, J., Bouvier, D., & Oris, C. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1129 · Cited by 8
Collij, L. E., Mattsson, N., Janelidze, S., Ossenkoppele, R., & Hansson, O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70763 · Cited by 9
Self-citationPlasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer’s disease
Guillén, N., Esteller, D., Sarto, J., Perales, I., Ríos, J., Massons, M., Martín-Sobrino, I., Auge, J. M., Naranjo, L., Ruiz‐García, R., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13556-5 · Cited by 8
Willemse, E. A. J., Sandgren, S., Benkert, P., Schaedelin, S. A., Maceski, A. M., Oechtering, J., Genc, N., Berger, K., Hermesdorf, M., Müller, S., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1480 · Cited by 8
Plasma GFAP as a mediator and moderator of Aβ, tau, and neurodegeneration in Alzheimer’s disease
Kim, J. S., Yi, D., Byun, M. S., Ahn, H., Jung, G., Choi, H., Lee, J., Kang, K. M., Chul-Ho, S., Lee, Y.-S., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00051-x · Cited by 8
Peng, J., Fan, T., Wang, J., Deng, Y., & Xu, R. (2026) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2026.2622722 · Cited by 8
Astrocytes and Memory: Implications for the Treatment of Memory-related Disorders
Wang, J., Cheng, P., Qu, Y., & Zhu, G. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240128102039 · Cited by 8
Biomarkers: Revolutionizing disease monitoring and therapeutic strategies
More, A., Kaur, S., Bhatele, S., Vasdev, N., Gupta, T., Pawar, B., & Tekade, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15842-1.00002-8 · Cited by 8
Blood diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis
Lv, Y.-T., & Li, H. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00286 · Cited by 8
Nan, 王. W., Yi, 刘. L., Jun, 张. Z., Shaohua, 何. H., Shihong, 侯. H., Shangyuan, 冯. F., & Duo, 林. L. (2024) · Chinese Journal of Lasers · doi:10.3788/cjl240805 · Cited by 8
Brezolin, É. C., Gayger-Dias, V., Silva, V.-F. D., Cigerce, A., Schultz, B., Sobottka, T. M., Nardin, P., de Assis, A. M., Leite, M. C., Quincozes‐Santos, A., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241289036 · Cited by 8
HMGA1 deficiency: a pathogenic link between tau pathology and insulin resistance
Mirabelli, M., CHIEFARI, E. D., Arcidiacono, B., Salatino, A., Pascarella, A., Morelli, M., Credendino, S. C., Brunetti, F. S., Vito, A. D., Greco, A., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105700 · Cited by 8
Wang, Z., Tan, L., Zong, Y., Ma, Y., Wang, Z., Initiative, A. D. N., Wang, H.-F., & Tan, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220725 · Cited by 8
Cheng, Y., Lin, Y., Lin, Y., Hong, W., Kuan, Y., Wu, K.-Y., Hsu, J., Wang, P., Pai, M., Chen, C., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.01.018 · Cited by 8
Blankenship, A. E., Kemna, R. E., Kueck, P. J., John, C. S., Vitztum, M., Yoksh, L., Mahnken, J. D., Vidoni, E. D., Morris, J. K., & Geiger, P. C. (2025) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00396.2024 · Cited by 7
Yang, J., Zhao, X., Liu, Y., Cai, Y., & Fan, Y. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100449 · Cited by 7
Misfolded Proteins and Cognitive Decline: Mechanistic Insights into Neurodegenerative Disorders
Duranti, E., & Villa, C. (2026) · Neurology International · doi:10.3390/neurolint18030048 · Cited by 7
Plasma proteomic signatures of preclinical Alzheimer’s disease in clinically unimpaired older adults
Trelle, A. N., Cody, K. A., Nguyen, T. T., Winer, J. R., Weiss, S., Sai, I., Ward, T., Cheng, G., Channappa, D., Mendiola, J. H., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00941-5 · Cited by 7
Gammaldi, N., Pezzini, F., Michelucci, E., Giorgi, N. D., Simonati, A., Rocchiccioli, S., Santorelli, F. M., & Doccini, S. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106349 · Cited by 7
Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease
Sintini, I., Singh, N. A., Li, D., Mielke, M. M., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., Graff‐Radford, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13713 · Cited by 7
Ohara, T., Tatebe, H., Hata, J., Honda, T., Shibata, M., Matsuura, S., Mikami, T., Maeda, T., Ono, K., Mimura, M., et al. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13661 · Cited by 7
Sun, Y., Xia, Q., Du, L., Gan, Y., Ren, X., Liu, G., Wang, Y., Yan, S., Li, S., Zhang, X., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116754 · Cited by 7
VandeBunte, A. M., Ortiz, B. L., Paolillo, E. W., Saloner, R., Diaz, V., Dutt, S., Cadwallader, C. J., Chen, C., Lago, A. L., Rojas, J. C., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01731-9 · Cited by 7
Zhang, Q., Yu, L.-K., Zhang, X.-Y., Wu, Y., Zhang, H., Wu, J.-L., Yao, Z., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352411 · Cited by 7
Glia inflammation and cell death pathways drive disease progression in preclinical and early AD
Woo, M. S., Therriault, J., Hosseini, S. A., Wang, Y.-T., Macedo, A. C., Rahmouni, N., Aumont, É., Servaes, S., Tissot, C., Arias, J. F., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00316-1 · Cited by 7
Self-citationMarzetti, E., Lorenzo, R. D., Calvani, R., Coelho‐Júnior, H. J., Landi, F., Pesce, V., & Picca, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411852 · Cited by 7
High-resolution omics of vascular ageing and inflammatory pathways in neurodegeneration
Kwok, A. J., Lu, J., Huang, J., Ip, B. Y. M., Mok, V., Lai, H. M., & Ko, H. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.06.005 · Cited by 7
Does Physical Exercise Modify the Pathophysiology of Alzheimer's Disease in Older Persons?
Raffin, J. (2024) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2024.11 · Cited by 7
Mandelblatt, J. S., Dage, J. L., Zhou, X., Small, B. J., Ahles, T. A., Ahn, J., Artese, A., Bethea, T. N., Breen, E. C., Carroll, J., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae113 · Cited by 7
Giudici, K. V., Barreto, P. D. S., Guyonnet, S., Cantet, C., Zetterberg, H., Boschat, C., Hudry, J., Andrieu, S., Schmitt, J. A. J., Vellas, B. J., et al. (2023) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2023.7 · Cited by 7
Self-citationGökçe, M., Velioğlu, H. A., Bektay, M. Y., & Güler, E. M. (2023) · Gerontology · doi:10.1159/000531849 · Cited by 6
Zhang, Y., Wang, J., Zhang, H., Tan, Z., Zheng, Y., Ping, J., Zhang, J., Luo, J., Li, L., Lu, L., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1461556 · Cited by 6
Daté, Y., Bun, S., Takahata, K., Kubota, M., Momota, Y., Iwabuchi, Y., Tezuka, T., Tabuchi, H., Seki, M., Yamamoto, Y., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01605-6 · Cited by 6
Wartchow, K. M., Rodrigues, L., Dartora, W. J., Biasibetti, R., Selistre, N. G., Lazarian, A., Castellanos, C. B., Bartelo, N., Gonçalves, C., McIntire, L. B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104810 · Cited by 6
GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome
Wanner, I. B., Halford, J., Lopez, J., Shen, S., Chen, Y., Zhao, H., Salas, C., Loo, R. R. O., Robicsek, S. A., Ellingson, B. M., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02240-y · Cited by 7
Bolton, C. J., Khan, O. A., Liu, D., Pechman, K. R., Gifford, K. A., Hohman, T. J., Blennow, K., Zetterberg, H., & Jefferson, A. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70796 · Cited by 6
Self-citationBlood biomarkers of seizures in epilepsy: machine learning reveals altered plasma proteome
Akel, S., Ashtiani, S. H., Sarangdhar, M. A., Axelsson, M., & Zelano, J. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2025-001321 · Cited by 6
Biomarker-integrated prognostic stagings for Alzheimer’s Disease
Shin, D., Lee, S., Kim, J. P., Jang, H., Yun, J., Chun, M. Y., Ahn, J., Kim, S., Kim, K., Yoon, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68732-6 · Cited by 6
Self-citationGórska, A. M., Santos‐García, I., Kvasnička, A., Dobešová, D., Friedecký, D., Gildenblat, J., & Pahnke, J. (2026) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2026.102891 · Cited by 6
Nanozymes Based Biosensors for Detection of Biomarkers in Brain Diseases
Teng, L., Tan, H., Bai, W., Yu, X., Li, Q., Wang, C., Zhang, H., Li, S., Yao, Y., Zhuang, W., et al. (2026) · Small · doi:10.1002/smll.202510732 · Cited by 6
Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility
Milà‐Alomà, M., Hausle, I., Myoraku, A., Sorensen, C., Thropp, P., Shaw, L. M. J., Weiner, M. W., Tosun, D., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71244 · Cited by 6
Chen, Y., Su, Y., Su, Y., Chen, K., Atri, A., Caselli, R. J., Reiman, E. M., Wang, Y., & Initiative, T. A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231162 · Cited by 6
Current status of prevention strategies adapted for Alzheimer's disease
Singh, A., Sethi, P., Ghosh, S., Singh, K. K., Rohatgi, S., Singh, P. K., & Sinha, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00004-5 · Cited by 6
Zhao, J., Zhao, D. B., Wang, J., Luo, X., & Guo, R. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221095383 · Cited by 6
Astroglial reactivity is a key modulator of Alzheimer’s disease pathological progression
Pelkmans, W., & Gispert, J. D. (2024) · Brain · doi:10.1093/brain/awae354 · Cited by 6
Humblet‐Baron, S., Feng, Y., Veiga, R., Neumann, J., Prezzemolo, T., Pasciuto, E., Vandenberghe, R., Yshii, L., & Liston, A. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70952 · Cited by 5
Wei, M., Yu, X., Hu, S., Hu, W., Shi, R., Wang, M., Zhong, J., Zhang, Q., Zhang, Y., Li, C., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309105 · Cited by 5
Anwar, M., Renu, K., Singh, A. K., Nayal, A. S., Thyagarajan, B., Hu, P., Lee, J., Dey, S., & Dey, A. B. (2025) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2025.e00455 · Cited by 5
Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum
Lee, S. Y., Diaz, V. E., Emanuel, O. M., Matusz, E. F., Webb, J. D., Chan, B., Lago, A. L., Wang, W., DeSimone, J. C., Rojas, J. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70626 · Cited by 5
Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions
Zheng, M., Wang, S., & Jia, J. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2554515 · Cited by 5
Development of language composites for enhanced sensitivity to multiple plasma biomarkers
He, D., Langhough, R. E., Hulle, C. V., Basche, K. E., Jonaitis, E. M., Wilson, R. H., Hermann, B. P., Zetterberg, H., Johnson, S. C., & Mueller, K. D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70975 · Cited by 5
Self-citationPatil, V., Sharma, A., Parekh, B. K., Jyothi.S, R., Priyadarshini‐Nayak, P., Janney-J, B., Singh, G., Al-Hasnaawei, S., & Kumar-Mishra, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05634-6 · Cited by 5
Giacomucci, G., Tabbì, S. M. R., Ingannato, A., Bagnoli, S., Padiglioni, S., Crucitti, C., Sensi, C., Sanesi, S., Moschini, V., Morinelli, C., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70285 · Cited by 5
Biosensors for detecting communicable and non-communicable diseases: A critical review
Mashayekh, N., & Khaledi, E. M. (2026) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2026.100986 · Cited by 5
Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis
Wilson, J. M., Dage, J. L., Qian, H., Irelan, C., Crowder, H. S., Duffin, K. L., Mintun, M., Brooks, D. A., Gerstein, H. C., & Bethel, M. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71391 · Cited by 5
LNC000152 Mediates Aluminum-Induced Proliferation of Reactive Astrocytes
Zhang, Z., Li, X., Ma, L., Wang, S., Zhang, J., Zhou, Y., Guo, X., & Niu, Q. L. (2024) · ACS Omega · doi:10.1021/acsomega.3c09702 · Cited by 5
Upregulation of Na/H Exchanger in Astrogliosis and Early Alzheimer’s Disease Pathogenesis
Collier, J. M., Metwally, S. A. H., McFarland, M., Krishna, S., Kurella, P., Fiesler, V. M., Stauffer, M. T., Begum, G., Kofler, J., & Sun, D. (2024) · Aging and Disease · doi:10.14336/ad.2024.1294 · Cited by 5
Zeiss, C. J., Huttner, A. J., Nairn, A. C., Arnsten, A. F. T., Datta, D., Strittmatter, S. M., Wyk, B. V., & Duque, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251323787 · Cited by 5
Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease
Yakoub, Y., Ashton, N. J., Karikari, T. K., Strikwerda‐Brown, C., Montoliu‐Gaya, L., Meyer, P., St‐Onge, F., Schöll, M., Breitner, J. C. S., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.064811 · Cited by 5
Self-citationWu, B., Chen, M., Meng, L., Tian, Q., & Dong, Z. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240096 · Cited by 5
A Mouse Model of Sporadic Alzheimer’s Disease with Elements of Major Depression
Бобкова, Н. В., Chuvakova, L. N., Kovalev, V. I., Zhdanova, D. Y., Chaplygina, A. V., Rezvykh, A. P., & Evgen’ev, M. B. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04346-7 · Cited by 6
Bettcher, B. M., Lopez‐Paniagua, D., Wang, Y., McConnell, B. V., Coughlan, C. M., Carlisle, T. C., Thaker, A. A., Lippitt, W., Filley, C. M., Pelak, V. S., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100834 · Cited by 4
Johansson, C., Þórðardóttir, S., Laffita‐Mesa, J. M., Pannee, J., Rodriguez‐Vieitez, E., Zetterberg, H., Blennow, K., & Graff, C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01574-w · Cited by 4
Self-citationAlishahi, F., Beam, C. R., Gatz, M., Schneider, L. S. S., Nation, D. A., Yassine, H. N., Kaplan, H. S., Ganesan, S., Pappas, I., Davis, D. W., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251340999 · Cited by 4
Graham, N., Zimmerman, K. A., Hain, J., Rooney, E. J., Lee, Y., Giovane, M. D., Parker, T. D., Wilson, M. G., Patel, M. C., Veleva, E., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336593 · Cited by 4
Self-citationMattsson, N., Karlsson, L., Tang, W., Blennow, K., Zetterberg, H., Bateman, R. J., Schindler, S. E., Barthélemy, N. R., Palmqvist, S., Stomrud, E., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00348-7 · Cited by 4
Self-citationKang, M., Lai, X., Wu, J., Xiang, Q., Chen, L., Li, X., Su, J. Z., Ma, Z., Wang, Y., Zhao, W., et al. (2025) · Anesthesiology · doi:10.1097/aln.0000000000005875 · Cited by 4
AD‐related plasma biomarkers in centenarians: links to cognition and neuropathology
Lorenz, L. M. C., Rohde, S. K., Luimes, M. C., Rozemüller, A. J. M., Bank, N. B., Hulsman, M., Graat, M. J. I., van der Hoorn, M. E., Daatselaar, D. A. H., Gouda, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70969 · Cited by 4
Self-citationGLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach
Santiago, J. A., Gutierrez-Silva, J. C., Hsu, W.-C., Sanchez, K., Almanza, C., Ramos, W., Haq, I. U., & Rundek, T. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.001 · Cited by 4
Systemic inflammation, delirium and clinical progression in mild-moderate Alzheimer disease
Dyer, A. H., Dolphin, H., Morrison, L., Kenny, T., Fallon, P. G., Cunningham, C. M., O’Connor, A., LAWLOR, B. A., O’Farrelly, C., Bourke, N. M., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106159 · Cited by 4
Plasma GFAP and Amyloid Pathology Predict Cognitive Response to Multidomain Interventions in MCI
Han, M., Hwang, M., Kwon, H. S., Moon, S. Y., Park, Y. K., Jeong, J. H., Choi, S. H., & Koh, S. (2025) · Aging and Disease · doi:10.14336/ad.2025.0646 · Cited by 4
Sota, R. E. D., Berghuis, B. A., Khoury, S., Zhuang, J., Rissman, R. A., Brewer, J. B., Quake, S. R., Sninsky, J. J., & Toden, S. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70152 · Cited by 4
Lohman, T., Sible, I. J., Kapoor, A., Engstrom, A. C., Shenasa, F., Alitin, J. P. M., Gaubert, A., Rodgers, K. E., Bradford, D. R., Mather, M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251376715 · Cited by 4
Analyzing the glial proteome in Alzheimer’s disease
Kim, J., Afridi, R., Lee, W., & Suk, K. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2260955 · Cited by 4
Plasma Neurodegenerative Biomarkers in Cognitively Preserved Nonagenarians
Gómez‐Tortosa, E., Agüero, P., Ruiz-González, A., Wagner, S., Téllez, R., Mahíllo, I., Ruiz-Calvo, A., Sainz, M. J., Nystrom, A. L., Cremades‐Jimeno, L., et al. (2024) · Aging and Disease · doi:10.14336/ad.2024.1260 · Cited by 4
Zetterberg, H. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326994 · Cited by 4
Self-citationFueling Alzheimer’s Disease: Where Does Immunometabolism Stand?
Correia, S. C., Perry, G. L., & Moreira, P. I. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240787 · Cited by 3
Idris, M., Saini, F., Ivain, P., Baksh, R. A., Bianchi, L. A., Pape, S. E., Zetterberg, H., Wijeratne, P. A., & Strydom, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70446 · Cited by 3
Self-citationEvaluation of a panel of plasma biomarkers for Alzheimer's disease in a diverse research cohort
DuBois, K. N., Pal, S., Reader, J. M., Jackman, B. M., Perkins, M., Khobeir, N., Bakulski, K. M., Heidebrink, J. L., Hampstead, B. M., Morgan, D., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251393405 · Cited by 3
Puech, C., Sadanand, A., Coleman, N., Ikhane, M., Badran, M., Wang, R., Gozal, D., & Parent, A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71134 · Cited by 3
A novel eye‐tracking digital marker outperforms plasma biomarkers in detecting cognitive impairment
Ling, Y., Sun, P., Wang, C., Peng, G., Wang, Y., Zhou, X., He, Z., Liu, B., Zhang, J., Yu, J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71253 · Cited by 3
Winiarczyk, D., & Winiarczyk, M. (2026) · Animals · doi:10.3390/ani16060930 · Cited by 3
Malotaux, V., Ku, V., Ospina-Lopera, P., Su, Y., Chen, Y., Singh, A., Ruiz-Triviño, J., Hidalgo, M. J., Osorio, L., Serna, L., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100578 · Cited by 3
Self-citationPeripheral biomarkers of neuroinflammation in Alzheimer’s disease and vascular dementia
Ouyang, X., Chia, R. S. L., Chai, Y. L., Chong, Sim, M. A., Jo, D., Arumugam, T. V., Sethi, G., Dawe, G. S., Chen, C. P., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118077 · Cited by 3
Zafari, R., Kamroo, A., Taherkhani, T., Nabizdeh, F., & Aarabi, M. H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.010 · Cited by 3
López‐Martos, D., Cacciaglia, R., Suárez‐Calvet, M., Salvadó, G., Shekari, M., González‐Escalante, A., Milà‐Alomà, M., Brugulat‐Serrat, A., Minguillón, C., Tonietto, M., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100612 · Cited by 3
Self-citationHeritability of Alzheimer's disease–related plasma biomarkers in the Amish population
Wang, P., Song, Y. E., Lynn, A., Miskimen, K. L. S., Gulyayev, A. V., Prough, M. B., Dorfsman, D. A., Laux, R. A., Fuzzell, S. L., Hochstetler, S. D., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70388 · Cited by 3
Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders
Teunissen, C. E., Vermunt, L., Barthélemy, N. R., Benzinger, T. L. S., Graff‐Radford, J., Verberk, I. M. W., Zetterberg, H., Schindler, S. E., & Jack, C. R. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(26)00246-2 · Cited by 3
Self-citation
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.